Takeda Pharma begins regulatory submissions for its dengue vaccine candidate to EMA :
Japan’s Takeda Pharmaceuticals has recently started the regulatory submissions for its dengue vaccine candidate to EMA. This was announced by the company on 25 March 2021. This vaccine is being developed for individuals aged 4 to 60. 
The drug firm stated that EMA would conduct an assessment of the vaccine called TAK – 003. This assessment allows EMA to assess and give opinions on medicines intended for use in countries outside the EU.
About Dengue Vaccine
A large–scale trial of this vaccine has already been conducted, and initial and additional data has been collected from it. The data revealed that the vaccine showed a successful result in children but had a shortcoming. It failed to protect against one of the four types of virus in children and teens who had not been previously – exposed to dengue.
Takeda has also added that it would submit the regulatory filings in certain Latin American and Asian countries in 2021. It also plans to submit a regulatory filing of this vaccine candidate in the US in 2021.
- European Medicines Agency
- European Union